AbbVie Explores Uncharted Territory With DUB Inhibitor Neuroscience Deal
Executive Summary
AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease.